Immix Biopharma Stock In The News

IMMX Stock  USD 2.11  0.14  7.11%   
Our overall analysis of Immix Biopharma's news coverage and content from conventional and social sources shows investors' bearish mood towards Immix Biopharma. The specific impact of Immix Biopharma news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Immix Biopharma's overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Immix Biopharma headlines in addition to utilizing other, more conventional financial analysis modules. Check out Immix Biopharma Backtesting and Immix Biopharma Hype Analysis.
For more information on how to buy Immix Stock please use our How to Invest in Immix Biopharma guide.

Immix Biopharma Today Top News and Investor Outlook

Macroaxis News: globenewswire.com
Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit
https://www.globenewswire.com/news-release/2023/11/30/2788706/0/en/Immix-Biopharma-to-Present-at-the-2023-JMP-Securities-Hematology-and-Oncology-Summit.html
 Neutral
Macroaxis News: globenewswire.com
Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis
https://www.globenewswire.com/news-release/2023/11/22/2784854/0/en/Immix-Biopharma-to-Host-KOL-Event-to-Discuss-its-BCMA-Targeted-CAR-T-Cell-Therapy-Candidate-NXC-201-for-Relapsed-Refractory-AL-Amyloidosis.html
 Neutral
Macroaxis News: globenewswire.com
La FDA approuve le dossier d’essai clinique de Immix Biopharma CAR-T NXC-201, et en permet ainsi l’administration aux patients américains
https://www.globenewswire.com/news-release/2023/11/22/2784589/0/fr/La-FDA-approuve-le-dossier-d-essai-clinique-de-Immix-Biopharma-CAR-T-NXC-201-et-en-permet-ainsi-l-administration-aux-patients-am%C3%A9ricains.html
 Neutral
Macroaxis News: globenewswire.com
Immix Biopharma gibt die FDA-Genehmigung des IND-Antrags für CAR-T NXC-201 bekannt, der die Verabreichung an US-Patienten ermöglicht
https://www.globenewswire.com/news-release/2023/11/22/2784589/0/de/Immix-Biopharma-gibt-die-FDA-Genehmigung-des-IND-Antrags-f%C3%BCr-CAR-T-NXC-201-bekannt-der-die-Verabreichung-an-US-Patienten-erm%C3%B6glicht.html
 Bearish
Macroaxis News: globenewswire.com
Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing
https://www.globenewswire.com/news-release/2023/11/21/2784152/0/en/Immix-Biopharma-Announces-FDA-Approval-of-IND-Application-for-CAR-T-NXC-201-Enabling-U-S-Patient-Dosing.html
 Neutral
Macroaxis News: globenewswire.com
Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing
https://www.globenewswire.com/news-release/2023/11/21/2784154/0/en/Immix-Biopharma-Announces-FDA-Approval-of-IND-Application-for-CAR-T-NXC-201-Enabling-U-S-Patient-Dosing.html
 Neutral
Macroaxis News: globenewswire.com
Nexcella Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients
https://www.globenewswire.com/news-release/2023/11/06/2774216/0/en/Nexcella-Presents-NXC-201-Data-at-65th-American-Society-of-Hematology-ASH-Annual-Meeting-in-9-Relapsed-Refractory-AL-Amyloidosis-Patients.html
 Neutral
Macroaxis News: globenewswire.com
Immix Biopharma Presents NXC-201 Data at...
https://www.globenewswire.com/news-release/2023/11/06/2774208/0/en/Immix-Biopharma-Presents-NXC-201-Data-at-65th-American-Society-of-Hematology-ASH-Annual-Meeting-in-9-Relapsed-Refractory-AL-Amyloidosis-Patients.html
 Neutral
Macroaxis News: globenewswire.com
Immix Biopharma Presents NXC-201 Data at...
https://www.globenewswire.com/news-release/2023/11/06/2774141/0/en/Immix-Biopharma-Presents-NXC-201-Data-at-65th-American-Society-of-Hematology-ASH-Annual-Meeting-in-63-Relapsed-Refractory-Multiple-Myeloma-Patients.html
 Neutral
Macroaxis News: globenewswire.com
Immix Biopharma Subsidiary Nexcella Anno...
https://www.globenewswire.com/news-release/2023/10/26/2767568/0/en/Immix-Biopharma-Subsidiary-Nexcella-Announces-Dr-Michaela-Liedtke-Stanford-Medicine-Cancer-Center-Hematology-Program-Lead-and-Co-Director-Stanford-Amyloid-Center-Joins-Scientific-A.html
 Neutral

Immix Biopharma Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Immix and other traded companies coverage with news coverage. We help investors stay connected with Immix headlines for the 30th of November to make an informed investment decision based on correlating the impacts of news items on Immix Stock performance. Please note that trading solely based on the Immix Biopharma hype is not for everyone as timely availability and quick action are needed to avoid losses.
Immix Biopharma's linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Immix Biopharma investors visualize upcoming and past events in order to time the market based on Immix Biopharma noise-free hype analysis.
Immix Biopharma stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Immix earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Immix Biopharma that are available to investors today. That information is available publicly through Immix media outlets and privately through word of mouth or via Immix internal channels. However, regardless of the origin, that massive amount of Immix data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Immix Biopharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Immix Biopharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Immix Biopharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Immix Biopharma alpha.

Immix Largest EPS Surprises

Earnings surprises can significantly impact Immix Biopharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2023-05-12
2023-03-31-0.14-0.18-0.0428 
2023-03-27
2022-12-31-0.22-0.27-0.0522 
2024-08-11
2024-06-30-0.21-0.150.0628 
2023-08-11
2023-06-30-0.17-0.24-0.0741 
2024-11-09
2024-09-30-0.16-0.24-0.0850 
View All Earnings Estimates

Immix Biopharma Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Immix Biopharma Stock. Current markets are slightly bearish. About 51% of major world exchanges and indexes are down. See today's market update for more information.
Macroaxis News: globenewswire.com
25th of November 2024
Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hemato...
at globenewswire.com 
Simply Wall St News at Macroaxis
11th of November 2024
Is Immix Biopharma In A Good Position To Deliver On Growth Plans
at simplywall.st 
Yahoo News
2nd of October 2024
Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidos...
at finance.yahoo.com 
Google News at Macroaxis
20th of September 2024
Immix Biopharma stock hits 52-week low at 1.74 amid market challenges - Investing.com
at news.google.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Immix Biopharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Immix Biopharma's short interest history, or implied volatility extrapolated from Immix Biopharma options trading.

Additional Tools for Immix Stock Analysis

When running Immix Biopharma's price analysis, check to measure Immix Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immix Biopharma is operating at the current time. Most of Immix Biopharma's value examination focuses on studying past and present price action to predict the probability of Immix Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immix Biopharma's price. Additionally, you may evaluate how the addition of Immix Biopharma to your portfolios can decrease your overall portfolio volatility.